What is the Bivalirudin?

Bivalirudin is White powder, while it's Molecular Formula is C98H138N24O33. White powder Anticoagulant; antithrombotic.

What is the CAS number for Bivalirudin?

The CAS number of Bivalirudin is 128270-60-0.

What is Bivalirudin (128270-60-0) used for?

Bivalirudin was launched in New Zealand as an anticoagulant for i.v. treatment ofpatients with unstable angina undergoing percutaneous transluminal coronary angioplasty.Bivalirubin is a synthetic 20 amino acid peptide rationally modeled on hirudin (residues 53-64), the most potent and specific naturally-occuring known inhibitor of thrombin, theenzyme that plays a key role in hemostasis and blood clot formation. This peptide is adirect thrombin inhibitor that maintains the unique bivalent binding properties of hirudin tothe catalytic site and to the fibrin-recognition exosite of the enzyme, so acting directly onthrombin with high affinity and specificity. In vitro studies demonstrated that alpha- andzeta-thrombins, both with the higher fibrinogen-procoagulant activities, were inhibited. Inrats receiving high doses of bivalirudin, the platelet deposition in carotide was reduced by63% compared to controls. The results of clinical studies, conducted only in patientsreceiving concomitant aspirin, suggested that the use of bivalirudin was more efficaciousand more predictable than unfractionated heparin, with fewer bleeding complications.Despite some unresolved developmental issues, the attractive properties of this novelagent could make it a useful alternative to heparin in a variety of coagulation disorders.InChI:InChI=1/C98H138N24O33/c1-5-52(4)82(96(153)122-39-15-23-70(122)92(149)114-60(30-34-79(134)135)85(142)111-59(29-33-78(132)133)86(143)116-64(43-55-24-26-56(123)27-25-55)89(146)118-67(97(154)155)40-51(2)3)119-87(144)61(31-35-80(136)137)112-84(141)58(28-32-77(130)131)113-88(145)63(42-54-18-10-7-11-19-54)117-90(147)66(45-81(138)139)110-76(129)50-107-83(140)65(44-71(100)124)109-75(128)49-106-73(126)47-104-72(125)46-105-74(127)48-108-91(148)68-21-13-38-121(68)95(152)62(20-12-36-103-98(101)102)115-93(150)69-22-14-37-120(69)94(151)57(99)41-53-16-8-6-9-17-53/h6-11,16-19,24-27,51-52,57-70,82,123H,5,12-15,20-23,28-50,99H2,1-4H3,(H2,100,124)(H,104,125)(H,105,127)(H,106,126)(H,107,140)(H,108,148)(H,109,128)(H,110,129)(H,111,142)(H,112,141)(H,113,145)(H,114,149)(H,115,150)(H,116,143)(H,117,147)(H,118,146)(H,119,144)(H,130,131)(H,132,133)(H,134,135)(H,136,137)(H,138,139)(H,154,155)(H4,101,102,103)/t52-,57+,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,82-/m0/s1

128270-60-0

Product NameBivalirudin
Molecular FormulaC₉₈H₁₃₈N₂₄O₃₃
Molecular Weight2180.31
Purity99%
AppearanceWhite powder

Inquiry

Product Details

Quick Details

CasNo： 128270-60-0
Molecular Formula： C₉₈H₁₃₈N₂₄O₃₃
Appearance： White powder
Purity： 99%

Chinese Manufacturer Supply Top Purity 99% Bivalirudin 128270-60-0 Cheapest Price

Molecular Formula:C98H138N24O33
Molecular Weight:2180.31
Appearance/Colour:White powder
Refractive Index:1.675
PSA：901.57000
Density:1.52 g/cm³
LogP:0.54320

Bivalirudin(Cas 128270-60-0) Usage

Description	Bivalirudin is a synthetic anticoagulant effective in preventing ischemic complications during angioplasty, with a favorable safety profile compared to traditional therapies. Its reversible nature, short half-life, and efficacy make it a suitable alternative in high-risk acute coronary syndrome patients. The ACUITY trial supports its use as a standalone treatment with reduced bleeding risks.
Chemical Composition and Origin	Bivalirudin is a synthetic novel anticoagulant. Developed by Swiss Basset (Biogen) and later transferred to the United States Medicines Company. Approved for marketing in the United States in 2000. Its anticoagulant ingredient is a 20-peptide derived from hirudin.
Mechanism of Action	Direct, specific, and reversible inhibitor of thrombin. Binds with both catalytic and anion binding sites of circulating or clot-bound thrombin. Inhibits thrombin activity, characterized by a short and reversible role.
Clinical Applications	Mainly used for preventing ischemic complications during angioplasty interventional treatment of unstable angina pectoris. Suitable for percutaneous coronary intervention (PCI) in cases of unstable angina. Demonstrates efficacy in reducing bleeding events, making it safer than traditional heparin therapy.
Originator	Biogen (US)
Definition	ChEBI: A synthetic peptide of 20 amino acids, comprising D-Phe, Pro, Arg, Pro, Gly, Gly, Gly, Gly, Asn, Gly, Asp, Phe, Glu, Glu, Ile, Pro, Glu, Glu, Tyr, and Leu in sequence. A congener of hirudin (a naturally occurring drug found in the saliva o the medicinal leech), it a specific and reversible inhibitor of thrombin, and is used as an anticoagulant.
Brand name	Angiomax (Medicinova).
Therapeutic Function	Anticoagulant

InChI:InChI=1/C98H138N24O33/c1-5-52(4)82(96(153)122-39-15-23-70(122)92(149)114-60(30-34-79(134)135)85(142)111-59(29-33-78(132)133)86(143)116-64(43-55-24-26-56(123)27-25-55)89(146)118-67(97(154)155)40-51(2)3)119-87(144)61(31-35-80(136)137)112-84(141)58(28-32-77(130)131)113-88(145)63(42-54-18-10-7-11-19-54)117-90(147)66(45-81(138)139)110-76(129)50-107-83(140)65(44-71(100)124)109-75(128)49-106-73(126)47-104-72(125)46-105-74(127)48-108-91(148)68-21-13-38-121(68)95(152)62(20-12-36-103-98(101)102)115-93(150)69-22-14-37-120(69)94(151)57(99)41-53-16-8-6-9-17-53/h6-11,16-19,24-27,51-52,57-70,82,123H,5,12-15,20-23,28-50,99H2,1-4H3,(H2,100,124)(H,104,125)(H,105,127)(H,106,126)(H,107,140)(H,108,148)(H,109,128)(H,110,129)(H,111,142)(H,112,141)(H,113,145)(H,114,149)(H,115,150)(H,116,143)(H,117,147)(H,118,146)(H,119,144)(H,130,131)(H,132,133)(H,134,135)(H,136,137)(H,138,139)(H,154,155)(H4,101,102,103)/t52-,57+,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,82-/m0/s1

128270-60-0 Relevant articles

AJIPHASE: A Highly Efficient Synthetic Method for One-Pot Peptide Elongation in the Solution Phase by an Fmoc Strategy

Takahashi, Daisuke,Inomata, Tatsuji,Fukui, Tatsuya

, p. 7803 - 7807 (2017)

We previously reported an efficient pept...

Harnessing polarity and viscosity to identify green binary solvent mixtures as viable alternatives to DMF in solid-phase peptide synthesis

Albericio, Fernando,Dettner, Frank,Egelund, Peter H. G.,Haselmann, Kim F.,Jadhav, Sandip,Johansson Castro, Henrik,Krüger, Tobias,Lechner, Carolin,Liffert, Raphael,Martin, Vincent,Pedersen, Daniel Sejer,Sch?nleber, Ralph,Thordal Le Quement, Sebastian

, p. 3295 - 3311 (2021)

Solid-phase peptide synthesis (SPPS) ena...

Protein Modification at Tyrosine with Iminoxyl Radicals

Ishiyama, Takashi,Kanai, Motomu,Maruyama, Katsuya,Oisaki, Kounosuke,Sakai, Kentaro,Seki, Yohei,Togo, Takaya

supporting information, p. 19844 - 19855 (2021/11/30)

Post-translational modifications (PTMs) ...

128270-60-0 Process route

HCl*H-D-Phe-Pro-Arg(Pbf)-Pro-Gly-Gly-Gly-Gly-Asn(Trt)-Gly-Asp(OtBu)-Phe-Glu(OtBu)-Glu(OtBu)-Ile-Pro-Glu(OtBu)-Glu(OtBu)-Tyr(tBu)-Leu-OKb, Kb=2,4-didocosyloxybenzyl: HCl*H-D-Phe-Pro-Arg(Pbf)-Pro-Gly-Gly-Gly-Gly-Asn(Trt)-Gly-Asp(OtBu)-Phe-Glu(OtBu)-Glu(OtBu)-Ile-Pro-Glu(OtBu)-Glu(OtBu)-Tyr(tBu)-Leu-OKb, Kb=2,4-didocosyloxybenzyl